Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 On 19thDecember 2014
Summary The industry analysis specialist, has released its new report, “Liposarcoma Therapeutics Pipeline Assessment and Market Forecasts to 2019�. The report is an essential source of information and analysis on the global Liposarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Liposarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Liposarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-liposarcoma-therapeutics-pipeline-assessment-and-market-forecasts135237 Scope The report provides information on the key drivers and challenges of the Liposarcoma Therapeutics market. Its scope includes Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Liposarcoma Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Liposarcoma Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Liposarcoma Therapeutics market. - Analysis of key recent licensing and partnership agreements in Liposarcoma Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Liposarcoma Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Liposarcoma Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global Liposarcoma Therapeutics market landscape? – Identify, understand and capitalize. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 Liposarcoma Therapeutics - Introduction 2.1 Disease Overview 2.1.1 Subtypes of Liposarcoma 2.2 Epidemiology 2.3 Etiology 2.4 Symptoms 2.5 Prognosis 2.6 Staging 2.6.1 Stage I 2.6.2 Stage II-III 2.6.3 Stage IV (metastatic) 2.7 Survival Rate 2.8 Risk Factors for Liposarcoma 2.9 Diagnosis 2.9.1 Biopsy 2.9.2 Computerized Tomography (CT) scan 2.9.3 Magnetic Resonance Imaging (MRI) 2.9.4 Positron Emission Tomography (PET) scan Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2.9.5 X-ray 2.10 Treatment of Liposarcoma 2.10.1 Surgery 2.10.2 Radiation 2.10.3 Chemotherapy 2.10.4 First-line therapy (The US, Europe and Japan) 2.10.5 Second-line therapy (The US, Europe and Japan) 2.10.6 Approved second-line/ third-line therapy in Europe 2.11 GlobalData Pipeline Report Guidance 3 Liposarcoma Therapeutics - Market Characterization 3.1 Liposarcoma Therapeutics Market Size (2006-2011) - Global 3.2 Liposarcoma Therapeutics Market Forecast (2011-2019) - Global 3.3 Liposarcoma Therapeutics Market Size (2006-2011) - the US 3.4 Liposarcoma Therapeutics Market Forecast (2011-2019) - the US 3.5 Liposarcoma Therapeutics Market Size (2006-2011) - the UK 3.6 Liposarcoma Therapeutics Market Forecast (2011-2019) –the UK 3.7 Liposarcoma Therapeutics Market Size (2006-2011) - France 3.8 Liposarcoma Therapeutics Market Forecast (2011-2019) - France 3.9 Liposarcoma Therapeutics Market Size (2006-2011) - Germany 3.10 Liposarcoma Therapeutics Market Forecast (2011-2019) - Germany 3.11 Liposarcoma Therapeutics Market Size (2006-2011) - Italy 3.12 Liposarcoma Therapeutics Market Forecast (2011-2019) - Italy 3.13 Liposarcoma Therapeutics Market Size (2006-2011) - Spain 3.14 Liposarcoma Therapeutics Market Forecast (2011-2019) - Spain 3.15 Liposarcoma Therapeutics Market Size (2006-2011) - Japan 3.16 Liposarcoma Therapeutics Market Forecast (2011-2019) - Japan 3.17 Drivers and Barriers for Liposarcoma 3.17.1 Drivers for the Liposarcoma Therapeutics Market 3.17.2 Barriers for the Liposarcoma Therapeutics Market 3.18 Opportunity and Unmet Needs 3.19 Key Takeaway 4 Liposarcoma Therapeutics Market - Competitive Assessment 4.1 Overview 4.1.1 Strategic Competitor Assessment 4.2 Product Profiles for the Major Products in Liposarcoma 4.2.1 Yondelis (trabectedin, ET-743) 4.2.2 Doxorubicin 4.2.3 Ifosfamide 4.3 Key Takeaway Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5 Liposarcoma Therapeutics - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.3 Pipeline Analysis by Phase of Development 5.3.1 Liposarcoma Therapeutics - Pre- registration 5.3.2 Liposarcoma Therapeutics - Phase III Pipeline 5.3.3 Liposarcoma Therapeutics - Phase II Pipeline 5.3.4 Liposarcoma Therapeutics - Phase I/II Pipeline 5.3.5 Liposarcoma Therapeutics - Phase I Pipeline 5.4 Liposarcoma Therapeutics - Pipeline by Mechanism of Action 5.5 Liposarcoma Therapeutics - Other Promising Mechanisms of Actions 5.6 Technology Trends Analytic Framework 5.7 Liposarcoma Therapeutics– Promising Drugs under Clinical Development 5.8 Molecule Profile for Drugs under Phase III Clinical Development 5.8.1 Ridaforolimus 5.8.2 TH-302 5.9 Key Takeaway 6 Liposarcoma Therapeutics - Clinical Trials Mapping 6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 6.2 Clinical Trials by Phase 6.3 Clinical Trials by Trial Status 6.4 Prominent Sponsors 6.5 Top Sponsors Participating in Liposarcoma Therapeutics Clinical Trials 7 Liposarcoma Therapeutics - Strategic Assessment 7.1 Future Market Competition Scenario 8 Liposarcoma Therapeutics - Future Players 8.1 Introduction 8.2 Company Profiles for the Marketed and Promising Drugs 8.2.1 Ariad Pharmaceuticals 8.2.2 Merck & Co. Inc. 8.2.3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C 8.2.4 PharmaMar S.A. 8.2.5 Threshold Pharmaceuticals 8.2.6 Merck Serono 8.3 Other Companies in the Liposarcoma Market, 2011 9 Liposarcoma Therapeutics - Licensing and Partnership Deals 10 Liposarcoma Therapeutics - Appendix 10.1 Market Definitions 10.2 Abbreviations Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
10.3 Methodology 10.3.1 Coverage 10.3.2 Secondary Research 10.3.3 Forecasting 10.3.4 Primary Research 10.3.5 Expert Panel Validation 10.4 Contact Us 10.5 Disclaimer 10.6 Bibliography
List Of Tables Table 1: Recurrence in subtypes of liposarcoma Table 2: Incidence of liposarcoma in Major Markets in 2011 Table 3: Five year survival rates for subtypes of liposarcoma Table 4: Surgical resection in liposarcoma Table 5: First-line therapy treatment for liposarcoma in G7 Table 6: Second-line therapy treatment for liposarcoma in G7 Table 7: Liposarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 Table 8: Liposarcoma Therapeutics Market, Global, Market Forecast ($m), 2011-2019 Table 9: Liposarcoma Therapeutics Market, the US, Revenue($m), 2006-2011 Table 10: Liposarcoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 Table 11: Liposarcoma Therapeutics Market, the UK, Revenue ($m), 2006-2011 Table 12: Liposarcoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 Table 13: Liposarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 Table 14: Liposarcoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 Table 15: Liposarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 Table 16: Liposarcoma Therapeutics Market, Germany, Market Forecast ($m),2011-2019 Table 17: Liposarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 Table 18: Liposarcoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 Table 19: Liposarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 Table 20: Liposarcoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 Table 21: Liposarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 Table 22: Liposarcoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 Table 23: Efficacy of trabectedin Table 24: Comparison of Yondelis adverse events with doxorubicin and ifosfamide Table 25: Liposarcoma Therapeutics - Pre-registration, 2011 Table 26: Liposarcoma Therapeutics - Phase III Pipeline, 2011 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 27: Liposarcoma Therapeutics - Phase II Pipeline, 2011 Table 28: Liposarcoma Therapeutics - Phase I/II Pipeline, 2011 Table 29: Liposarcoma Therapeutics - Phase I Pipeline, 2011 Table 30: Liposarcoma Therapeutics - Other Promising Mechanisms of Actions Table 31: Liposarcoam Therapeutics– Promising Drugs Under Clinical Development, 2011 Table 32: Patients characteristics in SUCCEED trial Table 33: PFS observed in SUCCEED trial Table 34: Adverse Events observed during SUCCEED trial Table 35: Adverse events observed with the class of mTOR inhibitors Table 36: Responses shown by soft tissue sarcoma group in TH-302 Phase II study Table 37: Adverse events of TH-302 Table 38: Hematologic Toxicity shown by TH-302 Table 39: Liposarcoma Therapeutics - Clinical Mapping by Region / Country, 2011 Table 40: Liposarcoma Therapeutics - Clinical Mapping by Phase, 2011 Table 41: Liposarcoma Therapeutics - Clinical Mapping by Trial Status, 2011 Table 42: Liposarcoma Therapeutics - Clinical Mapping by Overall Sponsors, 2011 Table 43: Liposarcoma Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 Table 44: Liposarcoma Therapeutics - Clinical Mapping by Top Sponsors, 2011 Table 45: Ariad Pharmaceuticals - Liposarcoma Pipeline Product, 2011 Table 46: Merck & Co. - Liposarcoma Pipeline Product, 2011 Table 47: Threshold Pharmaceuticals Inc. - Liposarcoma Pipeline Product, 2011 Table 48: Merck Serono - LiposarcomaTherapeutics Pipeline Table 49: Liposarcoma Therapeutics - Future Players, 2011 Table 50: Liposarcoma Therapeutics, Global, Deals
List Of Figures Figure 1: Characteristics of subtypes of liposarcoma Figure 2: Percentage split of subtypes of liposarcoma Figure 3: Yondelis treatment pathway as second/third line therapy Figure 4: Liposarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 Figure 5: Liposarcoma Therapeutics , Market Share (%), 2011 Figure 6: Liposarcoma Therapeutics Market, Global, Market Forecast ($m), 2011-2019 Figure 7: Liposarcoma Therapeutics, Market Share (%), 2019 Figure 8: Liposarcoma Therapeutics Market, the US, Revenue ($m), 2006-2011 Figure 9: Liposarcoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 Figure 10: Liposarcoma Therapeutics Market, the UK, Revenue ($m), 2006-2011 Figure 11: Liposarcoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 12: Liposarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 Figure 13: Liposarcoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 Figure 14: Liposarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 Figure 15: Liposarcoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 Figure 16: Liposarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 Figure 17: Liposarcoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 Figure 18: Liposarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 Figure 19: Liposarcoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 Figure 20: Liposarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 Figure 21: Liposarcoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 Figure 22: Liposarcoma Therapeutics - Drivers and Barriers, 2011 Figure 23: Opportunity and Unmet Need in Liposarcoma Therapeutics Market, 2011 Figure 24: Strategic Competitor Assessment of Liposarcoma Therapeutics Market, 2011 Figure 25: Liposarcoma Therapeutics Pipeline by Phase of Clinical Development, 2011 Figure 26: Liposarcoma Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 Figure 27: Technology Trends Analytic Framework of the Liposarcoma Therapeutics Pipeline, 2011 Figure 28: Technology Trends Analytic Framework of the Liposarcoma Therapeutics Pipeline Description, 2011 Figure 29: Response shown by liposaroma patients in TH-302 Phase II study Figure 30: Liposarcoma Therapeutics - Clinical Mapping by Region / Country, 2011 Figure 31: Liposarcoma Therapeutics - Clinical Mapping by Phase, 2011 Figure 32: Liposarcoma Therapeutics - Clinical Mapping by Trial Status, 2011 Figure 33: Liposarcoma Therapeutics - Clinical Mapping by Overall Sponsors, 2011 Figure 34: Liposarcoma Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 Figure 35: Liposarcoma Therapeutics - Clinical Mapping by Top Sponsors, 2011 Figure 36: Liposarcoma Therapeutics - Implications for Future Market Competition, 2011 Figure 37: Liposarcoma Therapeutics - Clinical Pipeline by Company, 2011 Figure 38: GlobalData Market Forecasting Model
Report Price: Licence Type
Price
$ 3995
Site Licence
$ 7990
Enterprise Wide Licence
$ 11985
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Related Reports: Pulmonary Embolism (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Vitiligo Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Chronic Urticaria or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Respiratory Syncytial Virus (RSV) Prophylactic - Pipeline Assessment and Market Forecasts to 2019 Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Clostridium difficile Infection (CDI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Haemophilus Influenzae Type B (Hib) Vaccine - Pipeline Assessment and Market Forecasts to 2019 Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 http://www.jsbmarketresearch.com/healthcare-medical/r-liposarcomatherapeutics-pipeline-assessment-and-market-forecasts-135237
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/